Huber Sara, Gadermaier Gabriele, Bohle Barbara, Ferreira Fatima, Briza Peter
Department of Biosciences, University of Salzburg, Salzburg, Austria.
Department of Pathophysiology and Allergy Research, Centre for Pathophysiology, Infectiology and Immunology, Medical University Vienna, Vienna, Austria.
World Allergy Organ J. 2021 Feb 26;14(3):100516. doi: 10.1016/j.waojou.2021.100516. eCollection 2021 Mar.
Skin prick test (SPT) solutions and allergy vaccines (AVs) are crucial tools for diagnosis and therapy of allergies. It was the aim of this study to corroborate the content of products for diagnosis and treatment of dust mite allergies that are produced and sold in India.
SDS-PAGE, immunoblots and high-resolution mass spectrometric analysis was performed with 16 house dust mite (HDM) SPT solutions and AVs from 3 Indian manufacturers. Authority-approved European SPT solutions and in-house extracts were used as references.
From the 5 Indian products, none contained proteins from this source. Instead, 1 sample contained and human serum proteins, 4 products contained allergens from the storage mite , allergens from the legume (chickpea), and proteins from baker's yeast. From 4 Indian labeled products, 2 contained human serum proteins and a limited number of allergens. Two contained only , , and yeast proteins. In contrast, the European authority-approved and SPT solutions that were used as reference in this study, contained exclusively proteins of the respective species and covered the expected allergen spectra. The sample contained no allergens at all, but consisted exclusively of , , and yeast proteins. All 6 HDM samples consisted of human serum proteins and limited amounts of allergens.
All commercial Indian SPT solutions and AVs analyzed in this study are not suitable for dust mite allergy diagnosis and therapy, as they contain either no, or only a limited number of, HDM allergens. In addition, their use could lead to misdiagnosis since some of them contain allergens from other sources, including the storage mite a, chickpea, as well as baker's yeast. Further, their application might be harmful to patients, as some products contain large amounts of proteins of human origin. Analysis of European SPT solutions, on the other hand, confirmed their suitability for dust mite allergy diagnosis.
皮肤点刺试验（SPT）溶液和过敏疫苗（AVs）是过敏诊断和治疗的关键工具。本研究的目的是证实印度生产和销售的用于诊断和治疗尘螨过敏的产品内容。
对来自3家印度制造商的16种屋尘螨（HDM）SPT溶液和AVs进行了SDS - PAGE、免疫印迹和高分辨率质谱分析。以权威认可的欧洲SPT溶液和内部提取物作为参考。
在5种印度产品中，没有一种含有来自该来源的蛋白质。相反，1个样品含有 和人血清蛋白，4种产品含有来自贮藏螨 的过敏原、来自豆科植物 （鹰嘴豆）的过敏原以及面包酵母的蛋白质。在4种印度标签产品中，2种含有人类血清蛋白和数量有限的 过敏原。2种仅含有 、 和酵母蛋白。相比之下，本研究中用作参考的欧洲权威认可的 和 SPT溶液仅含有各自物种的蛋白质，并涵盖了预期的过敏原谱。 样品根本不含有 过敏原，而是仅由 、 和酵母蛋白组成。所有6个HDM样品均由人血清蛋白和少量 过敏原组成。
本研究中分析的所有印度商业SPT溶液和AVs均不适合用于尘螨过敏的诊断和治疗，因为它们要么不含HDM过敏原，要么仅含有数量有限的HDM过敏原。此外，它们的使用可能导致误诊，因为其中一些含有来自其他来源的过敏原，包括贮藏螨 、鹰嘴豆以及面包酵母。此外，它们的应用可能对患者有害，因为一些产品含有大量的人类来源蛋白质。另一方面，对欧洲SPT溶液的分析证实了它们适用于尘螨过敏诊断。
